These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25548130)

  • 1. Regorafenib: start low and go slow.
    Tabchi S; Ghosn M
    Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: "Regorafenib: Start Low and Go Slow".
    de la Fouchardière C
    Target Oncol; 2016 Feb; 11(1):123-5. PubMed ID: 26634250
    [No Abstract]   [Full Text] [Related]  

  • 3. Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".
    Tabchi S; Ghosn M
    Target Oncol; 2016 Feb; 11(1):127-8. PubMed ID: 26645827
    [No Abstract]   [Full Text] [Related]  

  • 4. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
    Grothey A
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
    [No Abstract]   [Full Text] [Related]  

  • 5. Regorafenib in metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
    [No Abstract]   [Full Text] [Related]  

  • 6. Metastatic colorectal cancer.
    Prescrire Int; 2017 Feb; 26(179):51. PubMed ID: 30726636
    [No Abstract]   [Full Text] [Related]  

  • 7. [Regorafenib in patients with metastatic colorectal cancer: a review and an update].
    Zaniboni A; Mansueto G
    Recenti Prog Med; 2015 Dec; 106(12):629-33. PubMed ID: 26780072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib Also Can Cause Osteonecrosis of the Jaw.
    Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267
    [No Abstract]   [Full Text] [Related]  

  • 9. Regorafenib in the treatment of metastatic colorectal cancer.
    de la Fouchardière C
    Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
    Goldberg R
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
    Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular assessment of regorafenib monotherapy.
    Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
    Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regorafenib approved in Metastatic Colorectal cancer].
    André T; Dumont SN
    Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
    Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
    Draper A
    Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.
    Hofheinz RD; Arnold D; Kubicka S; Prasnikar N; Vogel A
    Oncol Res Treat; 2015; 38(6):300-8. PubMed ID: 26045027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
    Del Prete S; Cennamo G; Leo L; Montella L; Vincenzi B; Biglietto M; Andreozzi F; Prudente A; Iodice P; Savastano C; Nappi A; Montesarchio V; Addeo R
    Future Oncol; 2017 Feb; 13(5):415-423. PubMed ID: 27780365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
    Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.